Aarkstore - Frontier Pharma: Alzheimers Disease - Identifying and Commercializing First-in-Class Innovation - PowerPoint PPT Presentation

Loading...

PPT – Aarkstore - Frontier Pharma: Alzheimers Disease - Identifying and Commercializing First-in-Class Innovation PowerPoint presentation | free to download - id: 74966e-MGU0Y



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Aarkstore - Frontier Pharma: Alzheimers Disease - Identifying and Commercializing First-in-Class Innovation

Description:

The active Alzheimer’s Disease (AD) pipeline is populated with 583 products, with a highly diverse range of molecular targets. For more details : – PowerPoint PPT presentation

Number of Views:5

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Aarkstore - Frontier Pharma: Alzheimers Disease - Identifying and Commercializing First-in-Class Innovation


1
Aarkstore - Frontier Pharma Alzheimers Disease -
Identifying and Commercializing First-in-Class
Innovation
Pharmaceuticals Healthcare  Market Research
Reports
2
Summary
  • Large and Innovative Pipeline The active
    Alzheimers Disease (AD) pipeline is populated
    with 583 products, with a highly diverse range of
    molecular targets. GBI Research analysis revealed
    a high degree of innovation in this indication,
    with 46 of the pipeline being first-in-class
    products, acting on over 40 first-in-class
    molecular targets. In addition, the pipeline is
    characterized by the strong presence of therapies
    that target multiple components implicated in the
    amyloid cascade, several molecular targets of
    which are known to trigger familial AD. Given
    that the currently approved therapies for AD are
    limited to acetylcholinesterase inhibitors and
    glutamate receptor antagonists, the pipeline
    offers a broad range of treatment options that
    may possess disease-modifying properties.
    However, evaluation of the Preclinical and
    clinical evidence for their therapeutic potential
    reveals that the novelty of the molecular target
    is not sufficient to effectively reduce the rate
    of AD progression in human patients.

3
Scope
  • The report covers and includes - - A brief
    introduction to AD, including symptoms,
    pathophysiology, and overview of pharmacotherapy
    and treatment algorithms- The changing molecular
    target landscape between market and pipeline and
    particular focal points of innovation in the
    pipeline- A comprehensive review of the pipeline
    for first-in-class therapies, analyzed on the
    basis of stage of development, molecule type and
    molecular target- Identification and assessment
    of first-in-class molecular targets with a
    particular focus on early-stage programs for
    which clinical utility has yet to be evaluated,
    as well as literature reviews of novel molecular
    targets- Assessment of the licensing and
    co-development deal landscape for AD therapies
    and benchmarking of deals involving
    first-in-class versus non-first-in-class-products

4
Reasons to buy
  • The report will assist business development
    and enable marketing executives to strategize
    their product launches, by allowing them to - -
    Understand the focal shifts in molecular targets
    in the AD pipeline- Understand the distribution
    of pipeline programs by phase of development,
    molecule type and molecular target- Access a
    scientific and clinical analysis of
    first-in-class developmental programs for AD,
    benchmarked against non-first-in-class targets-
    Access a list of the first-in-class therapies
    potentially open to deal-making opportunities

5
Table of Content
  • 1.1 List of Tables 31.2 List of Figures
    32 Executive Summary 43 The Case for Innovation
    64 Clinical and Commercial Landscape 115
    Assessment of Product Pipeline Innovation 216
    Signaling Network, Genetics and Innovation
    Alignment 357 First-in-Class Target Evaluation
    398 Deals and Strategic Consolidations 759
    First-In-Class Molecules not Involved in
    Licensing or Co-development Deals 8610 Appendix
    89

6
List of Tables
  • Table 1 Mini-Mental State Exam, 2005 15Table 2
    Alzheimers Disease Assessment Scale, Cognitive
    Subscale, 1984 16

7
List Of Figures
  • Figure 1 Innovation Trends in Product Approvals,
    19872012 6Figure 2 Sales Performance of
    First-in-Class and Non-First-in-Class Product
    post Marketing Approval, 20062013 8Figure 3
    Sales Performance of Central Nervous System
    First-in-Class and Non-First-in-Class Products
    post Marketing Approval, 20062013 8Figure 4
    Alzheimers Disease, Global, Developmental
    Pipeline 22Figure 5 Alzheimers Disease,
    Global, Established and First-in-Class Pipeline
    25Figure 6 Alzheimers Disease, Global,
    Established Developmental Pipeline Part 1, 2014
    27Figure 7 Alzheimers Disease, Global,
    Established Developmental Pipeline Part 2, 2014
    28Figure 8 Alzheimers Disease, Global,
    Established Developmental Pipeline Part 3, 2014
    29Figure 9 Alzheimers Disease, Global,
    Established Developmental Pipeline Part 4, 2014
    30Figure 10 Alzheimers Disease, Global,
    First-in-Class Developmental Pipeline Part 1,
    2014 32

Browse full report Or Sample Request
_at_ http//www.aarkstore.com/pharmaceuticals-healthc
are/105777/frontier-pharma-alzheimers-disease-iden
tifying-and-commercializing-first-in-class-innovat
ion
8
Related Reports
  • 2015 Global Infectious Disease Molecular
    Diagnostics Market Country Forecasts, Supplier
    Shares, Emerging Technologies, Competitive
    Landscape
  • 2015 European Infectious Disease Molecular
    Diagnostics Market Country Forecasts, Supplier
    Shares, Emerging Technologies, Competitive
    Landscape
  • 2015 France Infectious Disease Molecular
    Diagnostics Market Country Forecasts, Supplier
    Shares, Emerging Technologies, Competitive
    Landscape
  • 2015 Germany Infectious Disease Molecular
    Diagnostics Market Country Forecasts, Supplier
    Shares, Emerging Technologies, Competitive
    Landscape
  • Global Healthcare IT Integration Market 2015-2019
  • Dialysis Catheters Market in the US 2015-2019
  • Global Immunodiagnostics Market 2015-2019
  • Pharmaceuticals Healthcare Market Research
    Reports

9
Follow Us
https//www.facebook.com/aarkstoredotcom
https//twitter.com/aarkstore
https//plus.google.com/Aarkstoredotcom/posts
https//www.linkedin.com/company/aarkstore-enterpr
ise
10
Contact Us
Office Address Office No. - 809, 8th
Floor,B-Wing, Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Mail us at
contact_at_aarkstore.com 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953
About PowerShow.com